Why this toolkit
Closing the gap between evidence and application
Congenital syphilis is preventable, yet screening and treatment coverage remain low across many high-burden countries. GC8 is a critical window to close that gap — and the application process requires documentation that most country teams haven't had to prepare before.
Translating evidence into required outputs
The evidence for dual HIV/syphilis testing is strong, but translating it into the specific outputs GC8 reviewers require — commodity quantities, landed cost budgets, narrative justifications — is a distinct and time-consuming task. This toolkit does that translation for you.
Works wherever you are starting from
Whether your country is procuring dual tests for the first time or scaling a commitment made in GC7, the tools adapt to your context. Hepatitis B integration is in development and will be incorporated in future versions.
Covering the full proposal lifecycle
The toolkit follows the GC8 process from country dialogue through pre-submission review. Each tool tells you when to use it, what it needs as input, and exactly where its output goes in the application.
Built for non-specialist audiences too
The Evidence Brief and narrative templates are designed to work in CCM meetings and MOH discussions, not just technical working groups — so the case for funding can be made at every level.
The tools
Four resources, used in sequence
Each tool covers a distinct stage of the GC8 application process, intended to be used in the order shown below. Open each item to see what it produces and when to use it.
A printable PDF user guide is also available, covering how to sequence the tools within the GC8 application timeline.
Start with the Checklist
The Syphilis Integration Checklist maps the full GC8 application timeline and sequences every required step. Return to it at each phase transition and before final submission.
Syphilis Integration Checklist Open first All phases — before country dialogue through pre-submission
A step-by-step reference guiding country teams through the actions required to include dual tests and BPG in a GC8 application, from country dialogue through submission. Items are organized across four phases — Before Country Dialogue, Country Dialogue and Gap Analysis, Application Development, and Pre-Submission Review — with a final cross-component consistency check to verify that quantities appear in all required locations of the application.
-
Key outputs
- Full application timeline and working schedule
- Phase-by-phase task list with syphilis-specific flags
- Toolkit cross-references at each step
- Pre-submission consistency check across all five required locations
Quantification & Budget Integrated Calculator Once targets confirmed Use when population, prevalence, and coverage targets are confirmed
An Excel-based tool that generates procurement quantities and budget figures for dual HIV/syphilis tests and BPG across a three-year grant period. Enter country population, prevalence, and coverage targets — the tool produces quantities, buffer stock, landed cost documentation, and a funding scenario analysis. Covers pregnant women and, optionally, other populations such as PLHIV or PWID.
-
Key outputs
- 3-year procurement quantities and buffer stock
- Landed cost budget (freight, customs, distribution)
- Funding scenario and coverage gap analysis
- Estimated adverse outcomes averted
Tutorial video
Impact Evidence Package During & after country dialogue Use when writing the funding narrative and programmatic gap analysis
Synthesizes published evidence in a format ready for use in funding applications. Draws on peer-reviewed studies, WHO guidance, and global market data, organized around the key sections of a GC8 proposal — including burden data, diagnostic evidence, treatment efficacy, and cost-effectiveness. Includes the Evidence Brief, a one-page version for stakeholder meetings and Ministry of Health engagement, as a standalone annex.
-
Key outputs
- Evidence summaries mapped to each proposal section
- Three proposal-ready narrative templates with placeholders
- Country adoption examples (Cameroon, Liberia, Zambia)
- Quick Reference single-table evidence summary
- Evidence Brief annex (also available standalone)
Evidence Brief Throughout Country dialogues, CCM meetings, MOH and donor discussions
A one-page version of the Impact Evidence Package, designed for stakeholder meetings and Ministry of Health engagement. Covers the scale of the problem, the solution, efficacy evidence, and cost-effectiveness in a format accessible to non-technical audiences. Included as an annex in the full Evidence Package and also available as a standalone document.
-
Key outputs
- Scale of the problem and the solution
- Efficacy evidence and cost-effectiveness summary
- GC8 strategic fit framing
Application integration
How the Tools Fit Together
Each tool feeds directly into one or more parts of the GC8 application — nothing requires duplication of effort.
| Tool | Feeds into the GC8 application |
|---|---|
| Syphilis Integration Checklist | Verifies that dual test and BPG outputs from all tools appear consistently across the programmatic gap analysis, HPMT, Detailed Budget, Performance Framework, and funding narrative before submission. |
| Quantification & Budget Calculator | Quantities and unit costs → HPMT. Budget totals → Detailed Budget. Executive Summary figures → funding narrative and programmatic gap table. |
| Impact Evidence Package | Narrative templates → funding narrative. Evidence summaries → programmatic gap analysis and value-for-money section. Evidence Brief (annex) → standalone advocacy use. |
| Evidence Brief | Used independently in country dialogues, CCM meetings, and donor discussions. |
Additional resources
Supporting References
External references that support the toolkit inputs and verify assumptions.
GC8 HIV Prioritization Guidance
The primary policy anchor for all GC8 narrative sections. Explicitly endorses HIV/syphilis dual RDTs as the first-line ANC test and lists BPG as a scaling priority.
WHO Triple Elimination Country Guidance
Programmatic context and country readiness frameworks for triple elimination of HIV, syphilis, and hepatitis B.
WHO Consolidated STI Operational Handbook
All WHO normative guidance on STI prevention, diagnosis, treatment, and surveillance — relevant for countries integrating syphilis into primary health care.
UNICEF Supply Catalog
BPG pricing reference. BPG 2.4 MIU: $0.39–$3.19 per dose. Use for BPG unit cost budgeting in the Calculator.
Global Fund PPM Reference Pricing
Negotiated pricing for dual HIV/syphilis tests. The Calculator auto-populates these prices; reference directly to verify or update unit costs.
Global Fund Price & Quality Reporting Database
Historical procurement data and supplier performance for benchmarking and supplier identification.
WHO Congenital Syphilis Estimation Tool
Country-level burden modeling tool for teams that want to run their own congenital syphilis estimates.
CHAI Integrated Screening Market Memo
Market information on triple HIV/syphilis/HBV tests. Relevant for countries evaluating dual vs. triple test procurement.